Authorization from Health Canada for Medical Device Investigational Testing

August 12, 2024, OPTITHERA obtained and Investigational testing authorization for medical devices from Health Canada, to sell its test for investigational testing to the investigators of the clinical study entitled: New Genomic predictor for complication risk in type 2 diabetes (GENOCORDIA). The objective of the study is to provide Real World Evidence (RWE) on the […]

Génome Québec allocates $ 1,9 M to the OPTITHERA project.

Génome Québec is particularly proud of the performance of Québec teams in a pan-Canadian competition. Over $23 million will be invested in genomics in Québec, including $5.4 million through Génome Québec. In fact, 49% of the available Canadian envelope was allocated to Québec projects. These investments will accelerate the commercialization and increase its real-world applications.

Innove-Action Conference @CHUM

Session on advances in personalized #medicine to improve prevention and treatment of chronic diseases. #innoveaction #chum #InnoveActionCHUM 

Polygenic risk: What’s the score?

Researchers are improving risk prediction for common chronic diseases using genetic data. These ‘polygenic risk scores’ can help personalize preventive measures and could soon become part of routine healthcare practice, once some limitations are overcome. Need more information about this research?

Upcoming test

Polygenic risk score for cardiorenal risk in subjects with type-2 diabetes